Long-term outcomes of two rescue therapies in lamivudine- refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
Korean Journal of Hepatology 2014³â 20±Ç 3È£ p.267 ~ p.273
Á¦Àº¿µ(Ze Eun-Young) - Chung-Ang University College of Medicine Department of Internal Medicine
¹éÀº°æ(Baek Eun-Kyung) - Chung-Ang University College of Medicine Department of Internal Medicine
ÀÌÁ¾Áø(Lee Jong-Jin) - Chung-Ang University College of Medicine Department of Internal Medicine
Á¤ÇÑ¿í(Chung Han-Wook) - Chung-Ang University College of Medicine Department of Internal Medicine
¾È´ë°Ç(Ahn Dae-Geon) - Chung-Ang University College of Medicine Department of Internal Medicine
Á¶È¯ÁØ(Cho Hwan-Jun) - Chung-Ang University College of Medicine Department of Internal Medicine
±ÇÀçö(Kwon Jae-Cheol) - Chung-Ang University College of Medicine Department of Internal Medicine
±èÇüÁØ(Kim Hyung-Joon) - Chung-Ang University College of Medicine Department of Internal Medicine
ÀÌÇö¿õ(Lee Hyun-Woong) - Chung-Ang University College of Medicine Department of Internal Medicine
Abstract
Background/Aims: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB). However, the long-term outcomes of LAM+ADV and 1-mg entecavir (ETV) rescue therapies have still been limited. The aim of this study was to determine the long-term outcomes of these two rescue therapies.
Methods: Sixty patients with LAM-r CHB underwent rescue therapy with LAM+ADV (n=36) or 1-mg ETV (n=24). We determined the duration of rescue therapy, timing and type of mutation, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower limitation of detection, <140 copies/mL), biochemical response (alanine aminotransferase <40 IU/ mL), and the incidence of hepatitis B virus e antigen (HBeAg) seroconversion and virologic breakthrough.
Results: Baseline characteristics did not differ between the two therapy groups. The duration of rescue therapy was 56 months (range, 14-100 months) in the ADV+LAM group and 42 months (range, 12-73 months) in the ETV group (P =0.036). The cumulative rates of HBV DNA undetectability and HBeAg seroconversion up to 6 years were 88.6% and 43.0%, respectively, in the ADV+LAM group, and 45.8% and 31.8% in the ETV group. The rate of virologic breakthrough and resistance was 14.4% in the ADV+LAM group and 71.9% in the ETV group (P =0.001).
Conclusions: Combination of LAM and ADV therapy for up to 6 years achieved modest rates of virological suppression and resistance. ETV is not an optimal therapy because the risk of viral breakthrough to ETV increases over time.
Å°¿öµå
Chronic hepatitis B, Lamivudine, Adefovir, Entecavir, Resistance
KMID :
1103920140200030267
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)